Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line
This article was originally published in The Pink Sheet Daily
Executive Summary
GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.
You may also be interested in...
FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says
Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.
GTx Files Toremifene For Prostate Cancer-Related Bone Loss
Biopharma is seeking a priority review for 80 mg toremifene, already marketed as Fareston at a 60 mg dose for breast cancer.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.